Clinical efficacy of SXBXW to Prevent the Restenosis After PCI in Patient with Coronary Artery DiseaseChinese Full Text
CHE Xian-da1,QING Lin-yan2,GAO Rui-lan2(1.Zhejiang Chinese Medical University,Huangzhou 310053,Zhejiang,China;2.Department of Cardiology,Zhejiang Provincial People’s Hospital,Hangzhou 310014,Zhejiang,China )
Abstract: Objective:To observe the clinical efficacy of Shexiang Baoxin Wan（SXBXW） to prevent the restenosis after PCI in patients with Coronary artery disease（CAD）.Methods:176 patients with CAD treated by PCI were randomly divided into two group:the control group:with general treated after PCI;the trial group:with general treated and SXBXW after PCI,and then to compare the difference between the two groups on the number of patients with angina,the clinical restenosis and restenosis of coronary arteriongraphy.Results:The number of bath patients of angina and the clinical restenosis in trail group were significant lower than that of patients in control group（P﹤0.005）,The number of patients of restenosis of coronary arteriongraphy in trail group was also significant lower than that of patients in control group（P﹤0.05）.Conclusion:SXBXW can prevent the restenosis after PCI in patients with CAD.
Keywords：
- DOI：
10.13193/j.archtcm.2008.04.94.chexd.025
- Series：
- Subject：
- Classification Code：
R259
- Mobile Reading
Read on your phone instantly
Step 1Scan QR Codes
"Mobile CNKI-CNKI Express" App
Step 2Open“CNKI Express”
and click the scan icon in the upper left corner of the homepage.
Step 3
Scan QR Codes
Read this article on your phone.
- HTML
- CAJ Download
- PDF Download
Download the mobile appuse the app to scan this coderead the article.
Tips: Please download CAJViewer to view CAJ format full text.
Download: 376 Page: 765-766 Pagecount: 2 Size: 77K
Citation Network
Related Literature
- Similar Article
- Reader Recommendation
- Associated Author